J.P. Morgan preparation for a biotech with an AI-approach

Challenge: A biotech company with an AI-approach to developing new TCRs for immunotherapy asked Alacrita to assist in preparations for the J.P. Morgan Healthcare conference. 
Learn More

Due diligence for a contract development & manufacturing organization

Challenge: A contract development and manufacturing organization (CDMO) was in negotiations to acquire two manufacturing sites from other companies. Under normal circumstances, the client would have...
Learn More

Triage DD of short bowel syndrome assets

Challenge: For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three...
Learn More

Valuation of a biotech company using Monte Carlo

Challenge: A biotechnology startup had entered a major licensing deal with Big Pharma and was able to fund operations via the upfront payment rather than needing to raise a Series A. This introduced...
Learn More

Due diligence on a bladder cancer gene therapy

Challenge: A European investment trust was considering an investment in a Phase 3 gene therapy opportunity targeting a niche oncology indication. Owing to the circumstances of the deal, they had less...
Learn More

Analysis of third party valuation for merger

Challenge: Our client, a publicly listed biotech company, was considering a merger with another publicly listed firm. To further initial discussions, a third-party valuation was commissioned on the...
Learn More

US and European partner outreach for Asian pharma companies

Challenge: A South Korean consulting firm required support in exploratory partner outreach in the US and Europe. Alacrita was commissioned to use its expertise in pharma licensing and deal-making in...
Learn More

Valuation of a lead pipeline agent

Challenge: A privately-funded preclinical stage biotech company asked Alacrita for a valuation of their lead pipeline agent for use in discussions with VC investors regarding their next financing...
Learn More

Technical & Commercial Due Diligence of a Portfolio of Biotech Companies

Challenge: A PE fund was looking at the potential purchase of a package of minority holdings in a portfolio of biotech companies on the secondary market. The fund approached Alacrita to conduct a due...
Learn More

Technical due diligence for a high-profile M&A transaction

Challenge: For a competitive M&A transaction, Alacrita was commissioned to conduct a technical due diligence of a major public drug delivery contract development and manufacturing organization. This...
Learn More

Due diligence on a product for ARDS in COVID-19 patients

Challenge: A family office was considering an investment in a US-based biotech company developing a product aimed at improving impaired oxygen transport in COVID-19 patients. Using its expert...
Learn More

Pre-DD on re-purposed CNS products

Challenge: A Middle Eastern VC firm was interested in a US-based drug re-purposing company and asked Alacrita to perform a high level technical due diligence exercise to help the firm make an...
Learn More
1 2 3 4 5 ... 11
Next
Content not found

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Life Science Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.